Inogen, Inc. (NASDAQ:INGN) Short Interest Update

Inogen, Inc. (NASDAQ:INGN - Get Free Report) was the recipient of a large decline in short interest in March. As of March 31st, there was short interest totalling 662,900 shares, a decline of 16.1% from the March 15th total of 790,000 shares. Approximately 2.8% of the shares of the company are sold short. Based on an average daily trading volume, of 336,200 shares, the short-interest ratio is currently 2.0 days.

Inogen Price Performance

Shares of Inogen stock traded down $0.23 on Friday, reaching $6.93. The company had a trading volume of 7,477 shares, compared to its average volume of 238,870. The firm has a market cap of $186.19 million, a price-to-earnings ratio of -3.08 and a beta of 1.48. The firm's 50-day moving average price is $7.65 and its two-hundred day moving average price is $9.07. Inogen has a 1 year low of $6.40 and a 1 year high of $13.33.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of Inogen in a report on Wednesday, April 9th. StockNews.com downgraded Inogen from a "buy" rating to a "hold" rating in a research note on Wednesday, February 26th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. AlphaQuest LLC purchased a new position in shares of Inogen during the fourth quarter valued at approximately $43,000. GAMMA Investing LLC grew its holdings in shares of Inogen by 5,738.9% in the first quarter. GAMMA Investing LLC now owns 5,547 shares of the medical technology company's stock worth $400,000 after purchasing an additional 5,452 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in Inogen in the 4th quarter worth about $56,000. Integrated Quantitative Investments LLC purchased a new position in Inogen in the 4th quarter worth about $92,000. Finally, Intech Investment Management LLC purchased a new stake in Inogen in the 4th quarter valued at about $94,000. 89.94% of the stock is owned by hedge funds and other institutional investors.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.